Emergent Health Corp (EMGE)

[powerbattles]

The statement below highlights our acquisition of Regen Biowellness, Inc. and Evolutionary Biologics, Inc., totaling 300,000 Series C Non-Voting Convertible Preferred Stock. Starting January 1, 2024, Series C Preferred Shares are eligible for conversion into Common Stock. In light of this, we must address these crucial questions:

1 - Why does the outstanding stock (o/s) remain unchanged?
2 - Who is the proprietor of Regen Biowellness, Inc. and Evolutionary Biologics? Stay tuned I will delve further into these details in part 3, providing information on products with issued patents and ImmunaZin containing an FDA approved.
3 - Who exercises control over the Series C Preferred Shares?

Note 10. Business Acquisition
On August 1, 2022 the Company acquired assets consisting of, but not limited to Corporate Name, Stock Holdings, Branding, Trademarks, Patents, IP, Formulations, Branding, and certain liabilities of Regen Biowellness, Inc., f/k/a Availa Bio, Inc. ("Regen"), a distributor of various products in the plant-based and regenerative medical fields. The acquisition was funded with 1,500,000 Series C Preferred Shares of Emergent. Effective January 1, 2024, Series C Preferred Shares can be converted into shares of Common Stock.On August 8, 2022, the Company acquired Evolutionary Biologics, Inc., a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. The purchase price included equity in Emergent and a capital investment into Evolutionary Biologics for sales, scaling of the company operations and promotions. Evolutionary Biologics flagship products include Evo Hybrid™ which helps jumpstart your body's own natural healing power to help bring your skin back to youthful suppleness and HydrEyes™ which helps reduce redness to help reveal your eyes' natural radiance. The acquisition was made for 1,500,000 Series C Preferred Shares of Emergent. Effective January 1, 2024, Series C Preferred Shares can be converted into shares of Common Stock. Series C Convertible Preferred Stock shall be converted into shares of Common Stock at the Conversion Rate of one hundred (100) shares for every one (1) share of Series C Convertible Preferred Stock

The keywords in the quote above are "CAN BE CONVERTED." If they have been converted, the outstanding shares (o/s) would increase by an additional 300 million. Now, let's delve deep to identify the owner of the Series C Convertible Preferred Stock.

Shares Outstanding on Date of This Report: Ending Balance: Date September 30, 2023, Common: 426,951,112
Preferred: Series A 100 ------ Series B 20,500,000 --------Series C 5,600,000

As you observe, the total outstanding shares of Series C amount to 5,600,000, which can be converted to common shares. However, the major control lies with Jim Morrison, the president and director.
James Zimbler's history raises several red flags, but fortunately, he only controls a portion of 1.5 million shares. Currently, he is no longer the CEO or president, that is great news for the stakeholder. Rest assured he is not the one taking full control of the company. From my point of view. To secure a stake in the future of the company, he must keep his shares locked up. James Zimbler has a dubious reputation, known for his manipulative tactics with shareholders. I don't like James Zimbler, but I must acknowledge his intelligence in recognizing Jim Morrison as the leader, prompting his step down from CEO to director and CFO. That explains why we see no dilution and the o/s continue to remain unchanged.


Series B Preferred Stock carries no voting rights, with a conversion rate of twenty (20) shares of common stock for every one (1) share of Series B. All Series B shares were issued on August 1, 2022, and the unrestricted ones have already been converted, totaling the outstanding Series B shares to 20,500,000, with only 1,250,000 remaining restricted, equivalent to 25,000,000 common C shares. This poses no cause for worry or concern on my part.